Ingenus, Not Leiutis, Can Press Cancer-Patent Suit, Judge Says

Ingenus Pharmaceuticals LLC can proceed alone in its cancer-drug patent suit against Nexus Pharmaceuticals Inc., a federal judge ruled, finding it kept the right to sue despite post-filing deals. Co-plaintiff Leiutis Pharmaceuticals LLP was dismissed from the case for lack of standing.

Leiutis relinquished all rights to US Patent No. 10,993,952 before trial, while Ingenus retained the legal authority to enforce it despite subsequently licensing the drug to Dr. Reddy’s Laboratories Ltd., Judge Mary M. Rowland ruled in an opinion issued May 6 in the US District Court for the Northern District of Illinois. She granted in part Nexus’s ...